Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Indian J Psychiatry. 2001 Jul;43(3):257-63.

Olanzapine in the treatment of schizophrenia : an open label comparative clinical trial from north India.

Author information

  • 1AJIT AVASTHI, MD., Additional Professor, Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh-160012.

Abstract

The aim of the present study was to assess the efficacy and safety of olanzapine in the treatment of schizophrenic patients. 27 patients were randomly assigned to treatment with olanzapine or haloperidol over 12 weeks. The primary efficacy measure was the mean change from baseline to endpoint in total scores on the Brief Psychiatric Rating Scale (BPRS) and assessing treatment emergent adverse events. Secondary measures were positive symptoms, negative symptoms, general psychopathology depression, anxiety and quality of life. Compared to haloperidol, olanzapine had equal effect in improving overall psychopathology, positive symptoms, and severity of schizophrenic illness. Olanzapine showed supehor improvement on negative symptoms and secondary depressive features. Commonest side effects were weight gain, sleepiness and increased duration of sleep. Olanzapine is effective in improving overall psychopathology including positive symptoms, negative and secondary depressive features in Indian patients with schizophrenia and it is safe and well tolerated at dosage between 5 to 20 mg/day.

KEYWORDS:

Olanzapine; schizophrenia; treatment

PMID:
21407865
[PubMed]
PMCID:
PMC2956152
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Write to the Help Desk